9728太阳集团-首页|welcome

Liangrunbio has always adhered to "technological innovation", relying on the discovery and verification of innovative protein biomarkers, especially exosome protein detection technology, and focusing on the development strategy of new immune products. It has applied for 32 independent innovation patent technologies, of which 17 have been authorized for invention patents. The company independently developed the world's first new marker of gastrointestinal cancer, CST4 kit (Elisa method), NMPA has been approved three types of registration certificate (National Instrument 20173403280) and CE certification; new lung cancer monitoring marker FXYD (chemiluminescence method) has been completed Clinical trials are about to apply for NMPA review; the new crown IgG/IgM kit (colloidal gold) has completed clinical trials and plans to apply for NMPA registration review; at the same time, it has also achieved independent research and development on key raw materials such as antigens and antibodies. The company has an independent scientific research laboratory of 800 square meters and a GMP standard modern workshop of 2000 square meters. It can produce more than 250 million people per year for the industrialization of diagnostic reagents, has passed the international ISO13485 quality system certification. In the next 2-3 years, it is expected that 3-5 international or domestic products will be launched one after another.